Ribupatide for Obesity and Diabetes

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Recruiting Phase 3 Interventional Study
Obesity With Diabetes Overweight With Diabetes
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
1,156 (estimated)
Sponsor
Kailera · Industry
Who this trial is looking for

This trial is looking for people with obesity or overweight who also have type 2 diabetes. Participants will receive a weekly injection of ribupatide to see how it affects their weight and blood sugar levels.

Are You a Good Fit for This Trial?
Must not be taking DPP-4 inhibitorsSemaglutideTirzepatide
Rules you out Type 1 diabetesHypoglycemiaDiabetic ketoacidosisPancreatitis

You may be able to join if

  • I have been diagnosed with type 2 diabetes
  • I have a BMI of 27 or higher
  • I have tried to lose weight with diet and exercise in the last 6 months
  • I have been on a stable diabetes treatment for at least 3 months

You may not be able to join if

  • I have a history of type 1 diabetes
  • I have had severe low blood sugar or diabetic ketoacidosis in the past year
  • I have changed my weight by more than 5% in the past 3 months
  • I have a history of pancreatitis
  • I have uncontrolled high blood pressure
  • I have a history of suicidal behavior
  • I have been diagnosed with a severe psychiatric disorder in the last 2 years

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Key Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus (T2DM). * Receiving stable therapy for T2DM for 3 months prior to Screening. This includes diet and/or exercise alone or in combination with any oral medication for T2DM treatment except for DPP-4 inhibitors. Participants can be treatm…
Contacts

Kailera Therapeutics, Inc.

1-781-317-0291

info-clinicalstudies@kailera.com

CONTACT